Abstract
The systematic review of the safety and efficacy of palivizumab in children with cystic fibrosis (CF) by Kua and Lee1 demonstrates the woeful lack of definitive data in this area and correctly points out the critical need for additional well-designed studies. Their review examined 10 scientific reports and concluded that respiratory syncytial virus (RSV) immunoprophylaxis “may have a potential role in reducing RSV hospitalizations in children aged less than 2 years with CF”.1 While we fully agree with the authors’ non-committal conclusions, it is important to highlight the extreme caution that must be exercised in interpreting this literature. This article is protected by copyright. All rights reserved.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
